temozolomide has been researched along with docetaxel anhydrous in 12 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 6 (50.00) | 29.6817 |
2010's | 6 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Bafaloukos, D; Briassoulis, E; Fountzilas, G; Georgoulias, V; Gogas, H; Kalofonos, Ch; Karabelis, A; Kosmidis, P; Samantas, E; Skarlos, D | 1 |
Aragoncillo, P; Casado Herraez, A; Díaz-Rubio García, E; Gómez Díaz, R; Moreno Antón, F; Puente Vázquez, J | 1 |
Earl, S; Gounaris, I; Lyons, B; Rahamim, J; Shivasankar, S; Yiannakis, D | 1 |
Burgess, TL; Coxon, A; Jun, HT; Kendall, R; Radinsky, R; Rex, K; Sun, J | 1 |
Bukowski, RM; Dreicer, R; Elson, P; Mekhail, T; Olencki, T; Roman, S; Tamaskar, I | 1 |
Bedikian, AY; Camacho, LH; Frost, AM; Hernandez, IM; Hwu, P; Hwu, WJ; Jack, MA; Kim, KB; Ng, C; Papadopoulos, NE | 1 |
Alvarado, GC; Bedikian, AY; Camacho, LH; Hwu, P; Kim, KB; McIntyre, S; Papadopoulos, NE; Yoon, C | 1 |
Aldrich, W; Triozzi, PL | 1 |
Alferez, D; Davies, BR; Heaton, SP; Heier, A; Holt, SV; Logié, A; Odedra, R; Smith, PD; Wilkinson, RW | 1 |
Becerra, CR; Braiteh, F; Chen, J; Chow, KH; Conkling, PR; Garbo, L; Ilaria, R; Jotte, RM; Richards, DA; Robert-Vizcarrondo, F; Smith, DA; Stephenson, J; Tai, DF; Turner, PK; Von Hoff, DD | 1 |
1 review(s) available for temozolomide and docetaxel anhydrous
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
4 trial(s) available for temozolomide and docetaxel anhydrous
Article | Year |
---|---|
Temozolomide in combination with docetaxel in patients with advanced melanoma: a phase II study of the Hellenic Cooperative Oncology Group.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Docetaxel; Female; Humans; Infusions, Intravenous; Male; Melanoma; Middle Aged; Neutropenia; Paclitaxel; Skin Neoplasms; Taxoids; Temozolomide; Thrombocytopenia | 2002 |
Phase I trial of weekly docetaxel and daily temozolomide in patients with metastatic disease.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasms; Survival Rate; Taxoids; Temozolomide | 2008 |
Phase I study of the combination of docetaxel, temozolomide and cisplatin in patients with metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Cohort Studies; Dacarbazine; Docetaxel; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Neoplasm Staging; Neutropenia; Pulmonary Embolism; Skin Neoplasms; Taxoids; Temozolomide; Treatment Outcome | 2009 |
An innovative, multi-arm, complete phase 1b study of the novel anti-cancer agent tasisulam in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cisplatin; Dacarbazine; Deoxycytidine; Docetaxel; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Quinazolines; Sulfonamides; Taxoids; Temozolomide; Young Adult | 2015 |
7 other study(ies) available for temozolomide and docetaxel anhydrous
Article | Year |
---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Cardiac metastasis from uterine leiomyosarcoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dacarbazine; Deoxycytidine; Diagnostic Errors; Docetaxel; Doxorubicin; Fatal Outcome; Female; Gemcitabine; Heart Neoplasms; Humans; Hysterectomy; Ifosfamide; Kidney Neoplasms; Leiomyoma; Leiomyosarcoma; Lung Neoplasms; Middle Aged; Ovariectomy; Taxoids; Temozolomide; Thoracic Surgery, Video-Assisted; Uterine Neoplasms | 2006 |
Marked response to a cisplatin/docetaxel/temozolomide combination in a heavily pretreated patient with metastatic large cell neuroendocrine lung carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Cisplatin; Dacarbazine; Docetaxel; Fatal Outcome; Female; Humans; Lung Neoplasms; Middle Aged; Quality of Life; Taxoids; Temozolomide | 2007 |
AMG 102, a fully human anti-hepatocyte growth factor/scatter factor neutralizing antibody, enhances the efficacy of temozolomide or docetaxel in U-87 MG cells and xenografts.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Docetaxel; Hepatocyte Growth Factor; Humans; Mice; Mice, Inbred Strains; Neoplasms; Taxoids; Temozolomide; Xenograft Model Antitumor Assays | 2007 |
The clinical efficacy of combination of docetaxel and temozolomide in previously treated patients with stage IV melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease Progression; Docetaxel; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Retrospective Studies; Skin Neoplasms; Taxoids; Temozolomide; Treatment Outcome | 2010 |
Effects of interleukin-1 receptor antagonist and chemotherapy on host-tumor interactions in established melanoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Antirheumatic Agents; Blotting, Western; Cell Proliferation; Dacarbazine; Docetaxel; Drug Therapy, Combination; Extracellular Fluid; Female; Flow Cytometry; Immunoenzyme Techniques; Interleukin 1 Receptor Antagonist Protein; Macrophages; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; T-Lymphocytes, Regulatory; Taxoids; Temozolomide; Tumor Cells, Cultured | 2010 |
The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzimidazoles; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Docetaxel; Female; Humans; MAP Kinase Kinase 1; MAP Kinase Kinase 2; MAP Kinase Signaling System; Mice; Mice, Nude; Mitogen-Activated Protein Kinase Kinases; Neoplasms, Experimental; Organophosphates; Protein Kinase Inhibitors; Quinazolines; Taxoids; Temozolomide; Xenograft Model Antitumor Assays | 2012 |